Table I. Activation phenotype profile in the four treatment groups of experimental sepsis
Cell PopulationsIRSh + ImipenemSaline + ImipenemIRShSaline
CD3+CD69+29.69 (15.42–43.95)60.67 (45.89–75.45)38.37 (33.96–42.78)55.17 (39.34–71.00)
(p = 0.0006) F (3, 23) = 11.81
CD3+CD44+CD69+32.24 (28.42–36.07)65.43 (55.59–75.27)48.10 (37.03–59.17)63.07 (51.79–74.36)
(p < 0.0001) F (3, 24) = 18.29
CD3+CD4+CD69+38.23 (30.37–46.09)53.34 (46.53–60.15)39.39 (35.32–43.46)52.47 (45.70–59.24)
(p = 0.0012) F (3, 24) = 10.94
CD3+CD4+CD44+CD69+39.94 (32.79–47.09)59.10 (32.79–85.41)44.67 (38.16–51.18)55.29 (46.05–64.53)
(p < 0.0001) F (3, 23) = 21.21
CD3+CD4+CD44+CD62L+CD69+43.29 (36.23–50.35)70.87 (59.57–82.17)49.23 (34.20–64.26)60.06 (52.54–67.58)
(p = 0.0004) F (3, 24) = 9.031
CD3+CD4+CD44+CD62LnegCD69+47.37 (40.26–54.48)60.74 (33.93–87.55)40.76 (22.65–58.87)59.20 (49.86–68.54)
(p < 0.0001) F (3, 22) = 19.32
CD3+CD8+CD69+13.97 (8.88–19.06)26.94 (20.28–33.60)51.11 (30.54–71.68)
(p = 0.0085) F (3, 24) = 11.50
CD3+CD8+CD44+CD69+25.57 (19.25–31.89)62.70 (46.52–78.88)44.26 (26.05–62.47)63.73 (43.73–83.73)
(p = 0.0012) F (3, 24) = 8818
CD3+CD8+CD44+CD62L+CD69+23.60 (17.95–29.25)62.66 (46.85–78.47)43.07 (24.89–61.25)63.21 (43.40–83.02)
(p = 0.0006) F (3, 24) = 9.901
CD3+CD4negCD8negCD69+26.90 (23.15–30.65)57.77 (48.17–67.37)38.13 (23.91–52.35)61.30 (45.62–76.98)
(p = 0.0003) F (3, 24) = 13.46
CD3+CD4negCD8negCD44+CD69+23.50 (19.85–27.15)54.59 (41.71–67.47)44.66 (26.43–62.89)59.04 (42.67–75.41)
(p = 0.0018) F (3, 24) = 8.990
CD3+CD4negCD8negCD44+CD62L+CD69+25.70 (21.27–30.13)60.60 (48.67–72.53)51.67 (31.15–72.19)65.03 (49.70–80.36)
(p = 0.0007) F (3, 24) = 10.60
CD3+CD4negCD8negCD44+CD62LnegCD69+24.93 (18.90–30.96)55.39 (48.47–62.31)45.84 (28.53–63.15)61.81 (43.46–80.16)
(p = 0.0015) F (3, 24) = 10.08
  • Results are means with 95% confidence intervals. The p value (IRSh + imipenem versus saline + imipenem) was calculated by ANOVA followed by Tukey multiple comparison posttest.